Frank Halley

Frank Halley currently works at the Medicinal Chemistry, Sanofi. Their most recent publication is 'Abstract P3-04-05: Identification of SAR439859, an orally bioavailable selective estrogen receptor degrader (SERD) that has strong antitumor activity in wild-type and mutant ER+ breast cancer models'.